Pravastatin sodium (CS-514) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
Pravastatin Sodium is an antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.